Suzanne Dahlberg

Senior Research Scientist
This email address is being protected from spambots. You need JavaScript enabled to view it.



Dr. Dahlberg provides statistical support for clinical trials and collaboration with investigators from the Dana-Farber Acute Lymphoblastic Leukemia Consortium and the Eastern Cooperative Oncology Group's Thoracic Committee.



Ph.D. Harvard University, 2005
B.S.   Tufts University, 2000 


Recent Publications

Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP,
Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA,
Ramalingam SS; ECOG-ACRIN 1512 Investigators. Erlotinib, cabozantinib, or
erlotinib plus cabozantinib as second-line or third-line treatment of patients
with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol.
2016 Dec;17(12):1661-1671.


Lampson BL, Nishino M, Dahlberg SE, Paul D, Santos AA, Jänne PA, Oxnard GR.
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. Cancer. 2016 Aug 15.


Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi
M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA. A
Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in
EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clin Cancer Res. 2016 Dec 15;22(24):6010-6020.


Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR
Jr, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016 Aug 1;122(15):2371-8.


Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, Mach SL,
Jänne PA, Oxnard GR. Prospective Validation of Rapid Plasma Genotyping for the
Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. 2016 Aug 1;2(8):1014-22.


Redig AJ, Capelletti M, Dahlberg SE, Sholl LM, Mach S, Fontes C, Shi Y,
Chalasani P, Jänne PA. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. Clin Cancer Res. 2016 Jul 1;22(13):3148-56.


Nishino M, Dahlberg SE, Fulton LE, Digumarthy SR, Hatabu H, Johnson BE,
Sequist LV. Volumetric Tumor Response and Progression in EGFR-mutant NSCLC
Patients Treated with Erlotinib or Gefitinib. Acad Radiol. 2016 Mar;23(3):329-36.


Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016 Mar 1;34(7):721-30.


Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, Johnson BE. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65.


Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Association
Between Younger Age and Targetable Genomic Alterations and Prognosis in
Non-Small-Cell Lung Cancer. JAMA Oncol. 2016 Mar;2(3):313-20.


Related Links


DFCI ALL Consortium

National Lung Cancer Partnership